期刊
JOURNAL OF PERSONALIZED MEDICINE
卷 13, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/jpm13091315
关键词
glioblastoma multiforme; valproic acid; HDAC; DNA damage response; double-strand break; synthetic lethality
This study demonstrates the potential of combining HDAC inhibitors with PARP1 inhibitors in inducing DNA damage and reducing glioblastoma. This combination therapy holds important implications for the treatment of glioblastoma, the most aggressive type of brain cancer.
HDAC inhibitors (HDACi) hold great potential as anticancer therapies due to their ability to regulate the acetylation of both histone and non-histone proteins, which is frequently disrupted in cancer and contributes to the development and advancement of the disease. Additionally, HDACi have been shown to enhance the cytotoxic effects of DNA-damaging agents such as radiation and cisplatin. In this study, we found that histone deacetylase inhibits valproic acid (VPA), synergized with PARP1 inhibitor (PARPi), talazoparib (BMN-673), and alkylating agent, and temozolomide (TMZ) to induce DNA damage and reduce glioblastoma multiforme. At the molecular level, VPA leads to a downregulation of FANCD2 and RAD51, and the eradication of glioblastoma cells. The results of this study indicate that combining HDACi with PARPi could potentially enhance the treatment of glioblastoma, the most aggressive type of cancer that originates in the brain.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据